The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Corporate Minority | Alive

Total Raised


Last Raised

$30M | 5 yrs ago

About FutuRx

FutuRx is the Israeli biotechnology incubator that was established in January 2014 by OrbiMed Israel Partners, Johnson & Johnson Innovation, JJDC, and Takeda Pharmaceutical Company, through its venture group Takeda Ventures.

FutuRx Headquarter Location

P.O.Box 4044

Ness Ziona, 7403635,



Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest FutuRx News

Cancer therapy co ImmPACT Bio raises $111m

Jan 20, 2022

Cancer therapy co ImmPACT Bio raises $111m Immpact was formed from a merger between US company Kalthera and a company founded in Israel's FutuRX biotech incubator. Israeli-American company ImmPACT Bio , which is developing the next generation of cancer cell therapies, has announced the completion of a $111 million financing round. ImmPACT Bio was formed a merger between Israeli company Immpact, which was raised in the FutuRX biotechnology incubator, and US company Kalthera, which was founded in the sector in California. RELATED ARTICLES FutuRX, headed by Erez Chimovits, is part of the Israel Innovation Authority's network of technological incubators, which is dedicated to drug development. The incubator franchisee is a consortium of the OrbiMed venture capital fund, Japanese pharmaceutical giant Takeda and Johnson & Johnson. OrbiMed participated in today's financing round, which was led by venBio Partners along with co-leads Foresite Capital and Decheng Capital along with Surveyor Capital and existing investors Novartis Venture Fund, RM Global Partners (RMGP), and Bukwang Pharmaceutical. Chimovits has until now been chairman. ImmPACT's logic-gate based CAR T platforms address key biological challenges in treating cancer. ImmPACT Bio's technologies are specifically designed to address antigen escape, 'on-target - off-tumor' toxicities, and the immunosuppressive tumor microenvironment. ImmPACT Bio has appointed Sumant Ramachandra as president and CEO. He said, "The US company brings with it two products, one of which is already in human clinic trials and one in advanced clinical trials." Both products are in the field of Tandem CAR, He added, "But the Israeli product is even more interesting. It is based on research by Prof. Gidi Gross from the Migal Institute. Gross was one of the researchers who wrote the article on which Kite pharma was based, and which is considered one of the pioneers in the CAR sector, and was which was acquired by Gilead for $11.9 billion." The company has two research centers in California and Israel and with the money raised it will build new research laboratories and a small production plant for therapies for clinical trials. The company has 23 employees and aims to increase the number to 65 by the end of the year. Published by Globes, Israel business news - - on January 20, 2022. © Copyright of Globes Publisher Itonut (1983) Ltd., 2022.

FutuRx Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

FutuRx Rank

  • Where is FutuRx's headquarters?

    FutuRx's headquarters is located at P.O.Box 4044, Ness Ziona.

  • What is FutuRx's latest funding round?

    FutuRx's latest funding round is Corporate Minority.

  • How much did FutuRx raise?

    FutuRx raised a total of $30M.

  • Who are the investors of FutuRx?

    Investors of FutuRx include RM Global Partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.